Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5885| Title: | Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination | Authors: | Sokal, A. Bastard, P. Chappert, P. Barba-Spaeth, G. Fourati, S. Vanderberghe, A. Lagouge-Roussey, P. Meyts, I. Gervais, A. Bouvier-Alias, M. Azzaoui, I. Fernández, I. de la Selle, A. Zhang, Q. Bizien, L. Pellier, I. Linglart, A. Rothenbuhler, A. Marcoux, E. Anxionnat, R. Cheikh, N. Léger, J. Amador-Borrero, B. Fouyssac, F. Menut, V. Goffard, J. C. Storey, C. Demily, C. Mallebranche, C. Troya, J. Pujol, A. Zins, M. Tiberghien, P. Gray, P. E. McNaughton, P. Sullivan, A. Peake, J. Levy, R. Languille, L. Rodiguez-Gallego, C. Boisson, B. Gallien, S. Neven, B. Michel, M. Godeau, B. Abel, L. Rey, F. A. Weill, J. C. Reynaud, C. A. Tangye, S. G. Casanova, J. L. Mahévas, M. |
Issue Date: | 2023 | Source: | J Exp Med, 2023 (220) 1 | Journal Title: | J Exp Med | Abstract: | Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines. | DOI: | 10.1084/jem.20220258 |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.